Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The AIR001-CS05 study evaluated the safety and efficacy (effectiveness) of AIR001 over 16
weeks in subjects who have PAH. The purpose of the AIR001-CS06 study is to evaluate the
intermediate / long-term safety of AIR001 in subjects who have completed the AIR001-CS05
study. Assessments to evaluate the effectiveness of the study drug will include measurements
of exercise ability and evaluations of PAH disease symptoms.